Tags

Type your tag names separated by a space and hit enter

Detection of antibodies to hepatitis C virus in U.S. blood donors.
J Clin Microbiol 1991; 29(3):551-6JC

Abstract

An enzyme immunoassay (EIA) which utilizes a solid phase coated with a recombinant antigen (c100-3) derived from the hepatitis C virus (HCV) genome was evaluated for efficacy in the detection of antibodies to HCV (anti-HCV). The sensitivity of the antibody test was demonstrated by the detection of anti-HCV in a well-characterized panel of human specimens known to contain the infectious agent of non-A, non-B hepatitis. The specificity of the anti-HCV test was evaluated by testing 6,118 serum specimens from volunteer blood donors considered to be at low risk for exposure to HCV. The specificity of the anti-HCV EIA was demonstrated to be 99.56%, since 6,069 of 6,096 specimens from this low-risk group were nonreactive. A total of 49 (0.80%) of the 6,118 specimens were repeatedly reactive in the test, and 22 (46.81%) of the 47 specimens available for additional testing were confirmed as positive for antibodies to HCV c100-3. Among commercial plasma donors, 390 (10.49%) of 3,718 specimens were repeatedly reactive in the EIA. A total of 375 (97.40%) of the 385 specimens available for further testing were confirmed as positive. These limited data indicate that the prevalence of antibodies to HCV is 0.36% (22 confirmed positives among 6,118 specimens) among volunteer blood donors and 10.08% (375 confirmed positives among 3,718 specimens) among commercial plasma donors. The importance of confirmatory testing is discussed.

Authors+Show Affiliations

Abbott Diagnostics Division, Abbott Laboratories, North Chicago, Illinois 60064.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1709949

Citation

Dawson, G J., et al. "Detection of Antibodies to Hepatitis C Virus in U.S. Blood Donors." Journal of Clinical Microbiology, vol. 29, no. 3, 1991, pp. 551-6.
Dawson GJ, Lesniewski RR, Stewart JL, et al. Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol. 1991;29(3):551-6.
Dawson, G. J., Lesniewski, R. R., Stewart, J. L., Boardway, K. M., Gutierrez, R. A., Pendy, L., ... Devare, S. G. (1991). Detection of antibodies to hepatitis C virus in U.S. blood donors. Journal of Clinical Microbiology, 29(3), pp. 551-6.
Dawson GJ, et al. Detection of Antibodies to Hepatitis C Virus in U.S. Blood Donors. J Clin Microbiol. 1991;29(3):551-6. PubMed PMID: 1709949.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of antibodies to hepatitis C virus in U.S. blood donors. A1 - Dawson,G J, AU - Lesniewski,R R, AU - Stewart,J L, AU - Boardway,K M, AU - Gutierrez,R A, AU - Pendy,L, AU - Johnson,R G, AU - Alcalde,X, AU - Rote,K V, AU - Devare,S G, PY - 1991/3/1/pubmed PY - 1991/3/1/medline PY - 1991/3/1/entrez SP - 551 EP - 6 JF - Journal of clinical microbiology JO - J. Clin. Microbiol. VL - 29 IS - 3 N2 - An enzyme immunoassay (EIA) which utilizes a solid phase coated with a recombinant antigen (c100-3) derived from the hepatitis C virus (HCV) genome was evaluated for efficacy in the detection of antibodies to HCV (anti-HCV). The sensitivity of the antibody test was demonstrated by the detection of anti-HCV in a well-characterized panel of human specimens known to contain the infectious agent of non-A, non-B hepatitis. The specificity of the anti-HCV test was evaluated by testing 6,118 serum specimens from volunteer blood donors considered to be at low risk for exposure to HCV. The specificity of the anti-HCV EIA was demonstrated to be 99.56%, since 6,069 of 6,096 specimens from this low-risk group were nonreactive. A total of 49 (0.80%) of the 6,118 specimens were repeatedly reactive in the test, and 22 (46.81%) of the 47 specimens available for additional testing were confirmed as positive for antibodies to HCV c100-3. Among commercial plasma donors, 390 (10.49%) of 3,718 specimens were repeatedly reactive in the EIA. A total of 375 (97.40%) of the 385 specimens available for further testing were confirmed as positive. These limited data indicate that the prevalence of antibodies to HCV is 0.36% (22 confirmed positives among 6,118 specimens) among volunteer blood donors and 10.08% (375 confirmed positives among 3,718 specimens) among commercial plasma donors. The importance of confirmatory testing is discussed. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/1709949/Detection_of_antibodies_to_hepatitis_C_virus_in_U_S__blood_donors_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=1709949 DB - PRIME DP - Unbound Medicine ER -